Overall drug spending rose 3% to $348bn in 2020, according to the latest US National Health Expenditures report. COVID-19 lowered drug utilization and spending, but not as much as it impacted health care services.
Patient out-of-pocket spending on prescription drugs covered by the retail pharmacy benefit declined 4.2% in 2020 due in part to use of coupons that lowered costs at the point of sale, according to the annual National Health Expenditures report released by the Centers for Medicare and Medicaid Services on 15 December.
The decrease in 2020 follows out-of-pocket spending increases of 3.5% in 2019 and 1.8% in 2018. The CMS report,...
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.
